Navigation Links
Axial Biotech appoints new Vice President of Strategic Initiatives
Date:9/5/2008

Industry Veteran is Well-Positioned to Expand Business Development Efforts

SALT LAKE CITY, Sept. 5 /PRNewswire/ -- Axial Biotech Inc., a company focused on the development of molecular diagnostic and motion preserving technologies in the spine care market, announced today that Joe Ross has joined the executive management team as the company's new Vice President of Strategic Initiatives.

In this new role, Ross will oversee Axial Biotech's global efforts to identify, evaluate, and pursue new diagnostic opportunities and will help to coordinate the company's long-term business strategy, solicit investment backing, and expand key development partnerships.

John Climaco, President and CEO of Axial Biotech, stated, "As we prepare for the commercial introduction of our DNA based prognostic test for Adolescent Idiopathic Scoliosis with our partners at DePuy Spine, we look forward to building on our successful research, and developing additional diagnostic tools to meet the clinical needs of today, and those anticipated in the future. Mr. Ross is uniquely qualified to drive this effort given his vast industry knowledge and experience, and successful track record of working closely with physician thought leaders to develop innovative clinical solutions."

Ross brings with him more than 12 years of experience in orthopedic medical devices and biologics. Prior to his most recent position as Vice President of Global Marketing for Stryker Biotech, Ross worked 11 years with the DePuy Spine division of Johnson and Johnson Corporation in roles of increasing responsibility including Worldwide Vice President for New Business Development. Ross has led numerous successful product and business development efforts and has been granted multiple U.S. patents. He is a graduate of the University of Notre Dame and Troy State University. He has also served five years as an officer in the United States Navy.

"I am thrilled to be joining the Axial Biotech team of accomplished researchers, clinicians and business professionals," said Ross. "The technologies being developed by Axial Biotech have the potential to transform not only the diagnostic process, but the identification and timing of the appropriate therapy, and ultimately to drive the development of revolutionary new treatments for multiple diseases of the spine. This is transformational technology that will significantly enhance patient outcomes and quality of life."

About Axial Biotech

Axial Biotech, Inc. develops molecular diagnostic assays and motion preservation technologies for common spinal diseases and disorders. Axial has developed the first DNA based prognostic test for Adolescent Idiopathic Scoliosis. Axial is accredited by the College of American Pathologists (CAP) and is certified to comply with the Clinical Laboratory Improvement Amendments (CLIA). Founded in 2002, Axial is based in Salt Lake City, Utah.


'/>"/>
SOURCE Axial Biotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Axial Biotech Names New VP of Reimbursement and Regulatory Affairs
2. Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing
3. BioMarin to Present at the Citi Biotech Day
4. /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
5. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
6. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
7. Preliminary Report of American Biotech Labs HIV Study Featured in Inaugural Issue of Journal of the Science of Healing Outcomes
8. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
11. BioSpace and BayBio announce 2008-2009 Biotech Bay(TM) Hotbed Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading ... the Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio ... and clinical trial team. , Using the CONSULT module, patients and physicians can schedule ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks ... to industrial engineering, was today awarded as one ... selection of the world,s most innovative companies. Ginkgo ... scale for the real world in the nutrition, ... engineers work directly with customers including Fortune 500 ...
(Date:6/24/2016)... ... 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona combed ... pleural mesothelioma. Their findings are the subject of a new article on the Surviving ... signposts in the blood, lung fluid or tissue of mesothelioma patients that can help ...
Breaking Biology Technology:
(Date:6/9/2016)... -- Paris Police Prefecture ... to ensure the safety of people and operations in several ... tournament Teleste, an international technology group specialised in ... that its video security solution will be utilised by ... safety across the country. The system roll-out is scheduled for ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, Biometrics & ... & Other Service  The latest report from ... of the global Border Security market . Visiongain ... billion in 2016. Now: In November 2015 ... and hardware technologies for advanced video surveillance. ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
Breaking Biology News(10 mins):